Primer Capital and the Ministry of Education and Science invest in TB drug development9 October 2017 The total amount of investments of Primer Capital and the Ministry of Education and Science of the Russian Federation is 44 million rubles.
According to WHO, there were an estimated 10.4 million new cases of TB disease worldwide in 2015.
The incidence of multidrug-resistant tuberculosis is increasing with nearly half of the cases reported in Russia, China and India. Over the past 40 years, no next generation drugs were developed, which resulted in consistent increase of bacterial resistance to existing agents.
MT-Medicals developed a highly specific inhibitor of cytochrome P450 enzymes that demonstrates high conservation, which greatly reduces the probability of tuberculosis bacterial resistance to the new treatment. Its use significantly optimizes the existing combined treatment regimens for resistant forms of tuberculosis and supports the individualization of such treatment.
“The main current trend in this field is the development of an effective medicinal compound to treat certain forms of tuberculosis infection. After successful registration of this product, it is planned to expand its spectrum of action on multiple forms of the disease,” comments Primer Capital COO Elizaveta Rozhdestvenskaya.
The investments will be used to develop finished dosage form manufacturing technologies and analytical methods for quality control, as well as to support preclinical product development.
Back to the list